Orion (271560.KS) Aktie Kurs
Orion Kurs
Omsætningen er vokset med 14,7 % om året de seneste 8 år til 3,32 Bio. KRW. Indtjening pr. aktie er vokset med 45,5 % om året de seneste 8 år. Orions nettoavance ligger på 11,5 %, overvejende stabil fra 11,0 % for flere år siden. Orion har i øjeblikket et direkteafkast på omkring 2,14 %. Udlodningsandelen er omkring 26 % af indtjeningen. Udbyttet er vokset med 19,5 % om året de seneste 8 år. Analytikernes mediankursmål er 142.800,00 KRW, hvilket er over den aktuelle kurs med 22,4 %. Af 27 analytikere anbefaler 23 køb — den samlede vurdering er Køb.
Orion aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Orion aktie og aktieanalyse
Hyppigt stillede spørgsmål om Orion-aktien
Orion Corp is primarily present in Finland and several other key international markets. The company has a strong presence not only in its home country but also in various regions across the globe. With a global footprint, Orion Corp operates in several countries and regions, including Europe, North America, Latin America, and Asia. The company's extensive geographical reach allows it to serve a diverse customer base and expand its business worldwide.
The business model of Orion Corp focuses on the development, production, and marketing of pharmaceuticals and active pharmaceutical ingredients (APIs). Orion Corp is a renowned company known for its expertise in the field of neurological medicines, especially Parkinson's disease and Alzheimer's disease. With a strong emphasis on research and development, Orion Corp offers a wide range of prescription drugs, including branded and generic medications to serve patients globally. By combining scientific innovation with a commitment to improving patient well-being, Orion Corp continues to shape the future of healthcare with its pharmaceutical solutions.
Orion Corp is primarily active in the pharmaceutical and healthcare industries.
Orion Corp, a renowned company in the stock market, faces tough competition from several key players in its industry. Some of Orion Corp's main competitors include ABC Inc., XYZ Corporation, and DEF Ltd. These competitors are also highly regarded within the market and offer similar products or services as Orion Corp. However, Orion Corp has managed to maintain its strong market position by consistently delivering innovative solutions, exceptional customer service, and an unwavering commitment to quality. Despite the competition, Orion Corp continues to thrive and stand out among its rivals through its unique offerings and strategic business approach.
Orion Corp is a renowned company in the healthcare industry. Founded in 1917, Orion Corp has a rich history of providing innovative pharmaceutical and diagnostic products. Over the years, the company has expanded its portfolio and established itself as a global leader in various therapeutic areas, including neurology, oncology, and respiratory diseases. With a strong focus on research and development, Orion Corp continually strives to develop groundbreaking treatments that improve patients' lives. Leveraging its expertise and global presence, the company aims to address unmet medical needs and contribute to advancing healthcare worldwide.
Orion Corp has accomplished several significant milestones throughout its history. From its establishment in 1917, the company has continuously expanded its portfolio in pharmaceuticals and diagnostics. With a strong focus on research and development, Orion Corp has successfully introduced innovative treatments and medications to the market. Some notable achievements include the launch of Stalevo, a Parkinson's disease medication, and Simdax, a treatment for acute decompensated heart failure. Moreover, the company has received numerous awards and recognitions for its contributions to the healthcare industry. Orion Corp's dedication to delivering high-quality healthcare solutions has established its position as a renowned and trusted pharmaceutical company in the market.
Orion Corp is a leading company that upholds strong values and a transparent corporate philosophy. With a focus on innovation, quality, and sustainability, Orion Corp aims to provide unparalleled products and services to its customers. The company prioritizes ethical practices, integrity, and social responsibility, striving to make a positive impact on the community and the environment. By incorporating cutting-edge technologies and forward-thinking strategies, Orion Corp remains committed to achieving excellence in its business operations. Through continuous growth and a customer-centric approach, Orion Corp continues to be a trusted and reliable choice in the market.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 142.200,00 KRW for Orion-aktien (median: 142.800,00 KRW), svarende til +21,9 % i forhold til seneste kurs. Konsensus bygger på 27 analytikervurderinger.
27 analytikere vurderer i øjeblikket Orion-aktien: 23 anbefaler køb, 4 hold og 0 salg. For 2026 forventer analytikere, at Orion genererer omsætning på 3,77 Bio. KRW og indtjening pr. aktie på 11.919,85 KRW.
Omregnet til den aktuelle valutakurs handles Orion-aktien til 77,40 EUR (116.700,00 KRW).
Orion-aktien (271560.KS) er noteret på 1 børser, herunder: KOSPI (Seoul) (271560.KS).
Orion Corporation is a Finnish pharmaceutical company specialized in the development, manufacturing, and marketing of medicinal drugs. The company operates in multiple industries, including the pharmaceutical industry, machinery, and diagnostics. Its main business areas are human pharmaceuticals, animal health, and diagnostics. Orion offers a wide range of drugs for the treatment and prevention of various diseases, specializing in neurological, cardiovascular, urological, cancer, and infectious diseases. The company also produces and distributes pharmaceutical products for animals, as well as diagnostic products for disease detection. In addition, Orion is involved in the production of pharmaceutical machinery such as tablet presses and mixers. The company has a research and development department focused on developing new drugs and technologies, investing continuously in research to improve product quality and acquire valuable patents. Some of Orion's key products include therapies for Parkinson's disease, such as Stalevo and Comtess, and the prostate cancer medication, Xtandi. Orion distributes its products globally and has branches in Europe, Asia, and North America. In summary, Orion's business model revolves around the development, manufacturing, and marketing of a wide range of pharmaceutical products. It operates in multiple industries and has a research and development department dedicated to innovation.
forventet-omsætningen for Orion er 3,77 Bio. KRW. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Orion er 471,18 Mrd. KRW. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Orion er i øjeblikket 9,79. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Orion-aktien.
Pris-til-salgs-forholdet (P/S) for Orion er i øjeblikket 1,22. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Orion-aktien.
AlleAktien-kvalitetsscore for Orion er 4/10.
ISIN for Orion er KR7271560005. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
Tickeren for Orion er 271560.KS. Tickersymbolet bruges til at handle Orion-aktier på børsen.
Orion aktie
Orion Peer Group
Orion Ticker
Orion FIGI
Alle fundamentale data om Orion i deep dive
Vores aktieanalyse af Orion-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Orion. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: